NCT05670561 is a Phase 4 clinical trial of Esketamine in Hepatocellular Carcinoma, sponsored by The Second Affiliated Hospital of Chongqing Medical University.

Who is sponsoring NCT05670561?

NCT05670561 is sponsored by The Second Affiliated Hospital of Chongqing Medical University.

What drugs are being tested in NCT05670561?

Interventions in NCT05670561: Esketamine, Sufentanil.

What condition does NCT05670561 study?

NCT05670561 studies Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Pain.

Is NCT05670561 still recruiting?

NCT05670561 is currently status unknown. Last updated 29 March 2023.

Last reviewed 2023-03-29 · How we verify

NCT05670561

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular Carcinoma

Status unknown Phase 4 Last updated 29 March 2023

What this trial tests

Phase 4 trial testing Esketamine in Hepatocellular Carcinoma in 60 participants. Status unknown.

Timeline

5 January 2023

Primary endpoint
30 June 2023

30 July 2023

Quick facts

Lead sponsor	The Second Affiliated Hospital of Chongqing Medical University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	5 January 2023
Primary completion	30 June 2023
Estimated completion	30 July 2023
Sites	1 location across China

Drugs / interventions tested

Esketamine (ESKETAMINE) — full drug profile →
Sufentanil (SUFENTANIL) — full drug profile →

Conditions studied

Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Transcatheter Arterial Chemoembolization — all drugs for Transcatheter Arterial Chemoembolization →
Pain — all drugs for Pain →

Sponsor

The Second Affiliated Hospital of Chongqing Medical University

Who can join

Adults 18 to 80, any sex, with Hepatocellular Carcinoma or Transcatheter Arterial Chemoembolization. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pain is the main complication after TACE(Transcatheter Arterial Chemoembolization) for hepatocellular carcinoma, and its pathogenesis is not clear.The pain may be related to partial liver tissue swelling after blocking the tumor blood supply artery embolization agent, transient hepatic swelling causing tension or strain on the liver capsule, and chemical irritation by the anticancer drug-Lipiodol mixture,the inadvertent embolization of normal organs and individual sensitivity to pain. Ketamine produces anesthetic and analgesic effects mainly by inhibiting NMDA receptor(N-methyl-D-aspartic acid receptor), and previous studies have shown that low concentrations of ketamine have obvious analgesic effects. Not only that, ketamine also produces analgesic effects by inhibiting opioid receptors via G-protein coupling. In addition, ketamine can bind to monoaminergic receptors in the central and peripheral nervous system, showing an anticholinergic effect and producing an antispasmodic effect. Ketamine also inhibits inflammatory pain by reducing nitric oxide production by inhibiting nitric oxide synthase. Esketamine is about three to four times more potent than ketamine. Therefore,esketamine requires a lower dose, about half the dose of ketamine, to produce anesthetic and analgesic effects, with fewer side effects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Emerging advances in drug delivery systems (DDSs) for optimizing cancer complications.
Li K, Guo B, Gu J, Ta N, et al · · 2025 · cited 8× · PMID 39759851 · DOI 10.1016/j.mtbio.2024.101375

Verify or expand the search:

Other trials of Esketamine

Trials testing the same drug.

NCT07315074 — Effect of Esketamine on Postoperative Sleep in Postmenopausal Women · NA · not yet recruiting
NCT07374458 — Effects of Esketamine and Bilateral Lower Limb Elevation on Hemodynamic Stability During Induction of General Anesthesia · NA · not yet recruiting
NCT07227454 — A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder · Phase 3 · recruiting
NCT06788444 — Efficacy of Esketamine for Patients With Irritable Bowel Syndrome · NA · recruiting
NCT07179913 — The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoper · Phase 4 · not yet recruiting

Other recruiting trials for Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting

Other The Second Affiliated Hospital of Chongqing Medical University trials

Trials by the same sponsor.

NCT07534046 — Impact of Metabolic Disorders on cACLD Outcomes · not yet recruiting
NCT07465003 — Cohort Study of Chronic Liver Disease Complicated by Sepsis · not yet recruiting
NCT07339644 — Functional Lung Avoidance Radiotherapy Guided by 4DCT Pulmonary Ventilation Function Imaging: A Prospective Single-arm C · NA · recruiting
NCT07048782 — Development and Validation of a Risk Prediction Model for Postoperative Visceral Pain in Abdominal Surgery Patients · not yet recruiting
NCT07033949 — Effect of Green Light Exposure at Different Times on the Pain of Subjects · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05670561 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Second Affiliated Hospital of Chongqing Medical University
Last refreshed: 29 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05670561.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing